Trials / Unknown
UnknownNCT00251849
PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients
Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 274 (planned)
- Sponsor
- ActivBiotics · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine whether rifalazil can significantly increase peak walking time (PWT) in patients with peripheral arterial disease (PAD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifalazil |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-12-01
- First posted
- 2005-11-11
- Last updated
- 2008-08-21
Locations
48 sites across 3 countries: United States, Brazil, Russia
Source: ClinicalTrials.gov record NCT00251849. Inclusion in this directory is not an endorsement.